BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23021913)

  • 1. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.
    Zougman A; Hutchins GG; Cairns DA; Verghese E; Perry SL; Jayne DG; Selby PJ; Banks RE
    Eur J Cancer; 2013 Jan; 49(2):531-9. PubMed ID: 23021913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
    den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
    Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients.
    El Gammal AT; Melling N; Reeh M; Gebauer F; Mann O; Perez D; Bockhorn M; Bachmann K; Izbicki JR; Grupp K
    Exp Mol Pathol; 2019 Apr; 107():51-56. PubMed ID: 30707896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAI3 expression is not associated with clinical outcomes of patients with non-small cell lung cancer.
    Melling N; Reeh M; Ghadban T; Tachezy M; Hajek A; Izbicki JR; Grupp K
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6549-6555. PubMed ID: 36781501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAI3 is overexpressed in gastric adenocarcinoma but unrelated to prognosis.
    Melling N; Bachmann K; Bockhorn M; Mann O; Izbicki JR; Grupp K
    Int J Clin Exp Pathol; 2019; 12(2):606-612. PubMed ID: 31933866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.
    Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z
    Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
    Allegra CJ; Paik S; Colangelo LH; Parr AL; Kirsch I; Kim G; Klein P; Johnston PG; Wolmark N; Wieand HS
    J Clin Oncol; 2003 Jan; 21(2):241-50. PubMed ID: 12525515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer.
    Jörissen H; Bektas N; Dahl E; Hartmann A; ten Haaf A; Di Fiore S; Kiefer H; Thess A; Barth S; Klockenbring T
    BMC Cancer; 2009 Jun; 9():200. PubMed ID: 19552806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic values of C‑X‑C motif chemokine ligand 3 in patients with colon cancer.
    Ruan GT; Gong YZ; Liao XW; Wang S; Huang W; Wang XK; Zhu GZ; Liao C; Gao F
    Oncol Rep; 2019 Nov; 42(5):1996-2008. PubMed ID: 31545503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications.
    Craig SG; Mende S; Humphries MP; Bingham V; Viratham Pulsawatdi A; Loughrey MB; Coleman HG; McQuaid S; Wilson RH; Van Schaeybroeck S; James JA; Salto-Tellez M
    Mol Oncol; 2021 Dec; 15(12):3317-3328. PubMed ID: 34428346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis.
    Flamini G; Curigliano G; Ratto C; Astone A; Ferretti G; Nucera P; Sofo L; Sgambato A; Boninsegna A; Crucitti F; Cittadini A
    Eur J Cancer; 1996 May; 32A(5):802-6. PubMed ID: 9081357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
    Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
    J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis.
    O'Dwyer D; Ralton LD; O'Shea A; Murray GI
    PLoS One; 2011; 6(11):e27718. PubMed ID: 22125622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of Src activation in stage II-III colon cancer.
    Martínez-Pérez J; Lopez-Calderero I; Saez C; Benavent M; Limon ML; Gonzalez-Exposito R; Soldevilla B; Riesco-Martínez MC; Salamanca J; Carnero A; Garcia-Carbonero R
    Hum Pathol; 2017 Sep; 67():119-125. PubMed ID: 28601656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.